Alterations of the dopamine transporter in resting lymphocytes of patients with different psychotic disorders

Psychiatry Research

Volumn 175, Issue 1-2, 2010, Pages 54-57

  Marazziti, Donatella ^a   Catena Dell'Osso, Mario ^a   Baroni, Stefano ^a   Masala, Irene ^a   Dell'Osso, Bernardo ^a,b   Consoli, Giorgio ^a   Giannaccini, Gino ^a   Betti, Laura ^a   Lucacchini, Antonio ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

3H WIN 35,428 binding; Bipolar disorders; Dopamine; Dopamine reuptake; Dopamine transporter; Humans; Resting lymphocytes; Schizophrenia

Indexed keywords

3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; DOPAMINE TRANSPORTER; TRITIUM;

ADULT; ARTICLE; BINDING AFFINITY; BRAIN REGION; CELL DENSITY; CLINICAL ARTICLE; CONTENT ANALYSIS; CONTROLLED STUDY; DOPAMINE UPTAKE; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN MODIFICATION; PSYCHOSIS;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CELL MEMBRANE; COCAINE; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; LYMPHOCYTES; MALE; PROTEIN BINDING; PSYCHOTIC DISORDERS; STATISTICS AS TOPIC; TRITIUM; YOUNG ADULT;

EID: 72149114082     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2009.03.009     Document Type: Article

References (45)

1. Amara S.G., and Kuhar M.J. Neurotransmitter transporters: recent progress. Annual Review of Neuroscience 16 (1993) 73-93
2. Amenta F., Bronzetti E., Felici L., Ricci A., and Tayebati S.K. Dopamine D2-like receptors on human peripheral blood lymphocytes: a radioligand binding assay and immunocytochemical study. Journal of Autonomic Pharmacology 19 (1999) 151-159
3. Amenta F., Bronzetti E., Cantalamessa F., El-Assouad D., Felici L., Ricci A., and Tayebati S.K. Identification of dopamine plasma membrane and vesicular transporters in human peripheral blood lymphocytes. Journal of Neuroimmunology 117 (2001) 133-142
4. American Psychiatric Association. DSM-IV. Diagnostic and Statistical Manual of Mental Disorders (2004), APA, Washington, DC
5. 125I]RTI-121 and other cocaine analogs in rat frontal cerebral cortex. Synapse 30 (1998) 9-17
6. Buttarelli F.R., Circella A., Pellicano C., and Pontieri F.E. Dopamine transporter immunoreactivity in peripheral blood mononuclear cells in amyotrophic lateral sclerosis. European Journal of Neurology 13 (2006) 416-418
7. Caronti B., Antonini G., Calderaro C., Ruggieri S., Palladini G., Pontieri F.E., and Colosimo C. Dopamine transporter immunoreactivity in peripheral blood lymphocytes in Parkinson's disease. Journal of Neural Transmission 108 (2001) 803-807
8. Carrera M.R., Meijler M.M., and Janda K.D. Cocaine pharmacology and current pharmacotherapies for its abuse. Bioorganic and Medicinal Chemistry 12 (2004) 5019-5030
9. Ciliax B.J., Drash G.W., Staley J.K., Haber S., Mobley C.J., Miller G.W., Mufson E.J., Mash D.C., and Levey A.I. Immunocytochemical localization of the dopamine transporter in human brain. Journal of Comparative Neurology 409 (1999) 38-56
10. 3H]dopamine uptake by platelets from subjects with active schizophrenia. Psychiatry Research 41 (1992) 17-24
11. 3H]dopamine uptake is differentially affected by neuroleptic drug treatment in schizophrenia and schizophreniform disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry 20 (1996) 45-55
12. Faraj B.A., Olkowski Z.L., and Jackson R.T. A cocaine sensitive active dopamine transport in human lymphocytes. Biochemical Pharmacology 50 (1995) 1007-1014
13. Fazzino F., Montes C., Urbina M., Carreira I., and Lima L. Serotonin transporter is differentially localized in subpopulations of lymphocytes of major depression patients. Effect of fluoxetine on proliferation. Journal of Neuroimmunology 196 1-2 (2008) 173-180 May 30
14. First M.B., Spitzer R.L., Gibbon M., and Williams J.B.W. Structured Clinical interview for DSM-IV Axis I disorders - Patient Edition (SCID-I/P, Version 2.0, 4/97 revision). Biometrics Research Department, New York State Psychiatric Institute (1997)
15. Frankhauser P., Grimmer Y., Bugert P., Deuschle M., Schmidt M., and Schloss P. Characterization of the neuronal dopamine transporter DAT in human blood platelets. Neuroscience Letters 399 (2006) 197-201
16. Giros B., El Mestikawy S., Bertrand L., and Caron M.G. Cloning and functional characterization of a cocaine-sensitive dopamine transporter. FEBS Letters 295 (1991) 149-154
17. Gordon J., and Barnes N.M. Lymphocytes transport serotonin and dopamine: agony or ecstasy?. Trends in Immunology 24 (2003) 438-443
18. Guzey C., Scordo M.G., Spina E., Landsem V.M., and Spigset O. Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: associations with dopamine and serotonin receptor and transporter polymorphisms. European Journal of Clinical Pharmacology 63 (2007) 233-241
19. 3H]GBR 12935 binding site density in the prefrontal cortex of controls and schizophrenics. Biological Psychiatry 37 (1995) 175-182
20. Hsiao M.C., Lin K.J., Liu C.Y., Tzen K.Y., and Yen T.C. Dopamine transporter change in drug-naive schizophrenia: an imaging study with 99mTc-TRODAT-1. Schizophrenia Research 65 (2003) 39-46
21. 3H]GBR 12935 (1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)-piperazine) to membranes and to solubilized membrane extracts from terminal field regions of mesolimbic, mesocortical and nigrostriatal dopamine pathways. Neuropharmacology 29 (1990) 1017-1024
22. 3H]-dopamine uptake displayed by native lymphocyte suspensions is mainly due to contaminating platelets. Pharmacopsychiatry 31 (1998) 193-198
23. Laakso A., Vilkman H., Alakare B., Haaparanta M., Bergman J., Solin O., Peurasaari J., Rakkolainen V., Syvalahti E., and Hietala J. Striatal dopamine transporter binding in neuroleptic-naive patients with schizophrenia studied with positron emission tomography. American Journal of Psychiatry 157 (2000) 269-271
24. Laakso A., Bergman J., Haaparanta M., Vilkman H., Solin O., Syvalahti E., and Hietala J. Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia. Schizophrenia Research 52 (2001) 115-120
25. 123I]beta-CIT. Biological Psychiatry 47 (2000) 371-379
26. Lima L., and Urbina M. Serotonin transporter modulation in blood lymphocytes from patients with major depression. Cellular and Molecular Neurobiology 22 (2002) 797-804
27. Lingjaerde O. Dopamine uptake in platelets. Biological Psychiatry 38 (1995) 416-417
28. 125I]RTI-121 binding sites in human striatum and medial temporal lobe. The Journal of Pharmacology and Experimental Therapeutics 274 (1995) 1473-1483
29. Marazziti D., Rossi A., Giannaccini G., Baroni S., Lucacchini A., and Cassano G.B. Presence and characterization of the serotonin transporter in human resting lymphocytes. Neuropsychopharmacology 19 (1998) 154-159
30. 3H-WIN-35,428 and 125I-RTI-121 to human platelet membranes. Neurochemical Research 31 (2006) 361-365
31. Marazziti D., Baroni S., Dell'Osso Catena M., Masala I., Fabbrini L.B., Betti L., Giannaccini G., and Lucacchini A. Presence and characterization of the dopamine transporter in human resting lymphocytes. Neurochemical Research 33 (2008) 1011-1116
32. 123I] FP-CIT in first-episode schizophrenic patients with and without short-term antipsychotic-induced parkinsonism. Psychopharmacology 181 (2005) 401-406
33. Mateos J.J., Lomena F., Parellada E., Mireia F., Fernandez-Egea E., Pavia J., Prats A., Pons F., and Bernando M. Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait. Psychopharmacology 191 (2007) 805-811
34. McPherson G.A. Kinetic, EBDA, Ligand, Lowry: A collection of Radioligand Binding Analysis Programs (1985), Biosoft, Cambridge
35. Mill J., Asherson P., Browes C., D'Souza U., and Craig I. Expression of the dopamine transporter gene is regulated by the 3′ UTR VNTR: evidence from brain and lymphocytes using quantitative RT-PCR. American Journal of Medical Genetics 114 (2002) 975-979
36. Nie N.H., Hull C.H., Steinbrenner K., and Bent D.H. Statistical Package for the Social Science (SPSS), 4th ed (1998), Mc Graw-Hill, New York
37. Overall J.E., and Gorham D.R. The Brief Psychiatric Rating Scale. Psychological Reports 10 (1962) 799-812
38. Pellicano C., Buttarelli F.R., Circella A., Tiple D., Giovannelli M., Benincasa D., Colosimo C., and Pontieri F.E. Dopamine transporter immunoreactivity in peripheral blood lymphocytes discriminates Parkinson's disease from essential tremor. Journal of Neural Transmission 29 (2007)
39. 3H]dopamine uptake by platelet storage granules in schizophrenia. Life Sciences 50 (1992) 65-72
40. Rotman A., Munitz H., Modai I., Tjano S., and Wijsenbeek H. A comparative uptake study of serotonin, dopamine, and norepinephrine by platelets of acute schizophrenic patients. Psychiatry Research 3 (1980) 239-246
41. Schmitt G.J., Meisenzahl E.M., Frodl T., La Fougere C., Hahn K., Moller H.J., and Dresel S. The striatal dopamine transporter in first-episode, drug-naive schizophrenic patients: evaluation by the new SPECT-ligand[99mTc]TRODAT-1. Journal of Psychopharmacology 19 (2005) 488-493
42. Sjoholm H., Bratlid T., and Sundsfjord J. 123I-beta-CIT SPECT demonstrates increased presynaptic dopamine transporter binding sites in basal ganglia in vivo in schizophrenia. Psychopharmacology 173 (2004) 27-31
43. 123I]-beta-CIT SPECT-study. European Neuropsychopharmacology 11 (2001) 69-74
44. Thirthalli J., and Benegal V. Psychosis among substance users. Current Opinion in Psychiatry 19 (2006) 239-245
45. Yang Y.K., Yu L., Yeh T.L., Chiu N.T., Chen P.S., and Lee I.H. Associated alterations of striatal dopamine D2/D3 receptor and transporter binding in drug-naive patients with schizophrenia: a dual-isotope SPECT study. American Journal of Psychiatry 161 (2004) 1496-1498